Regadenoson
- Generic Name
- Regadenoson
- Brand Names
- Lexiscan, Rapiscan
- Drug Type
- Small Molecule
- Chemical Formula
- C15H18N8O5
- CAS Number
- 313348-27-5
- Unique Ingredient Identifier
- 7AXV542LZ4
- Background
Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.
- Indication
Diagnostic agent for radionuclide myocardial perfusion imaging (MPI)
A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease
- Conditions
- AsthmaCoronary Artery DiseasePulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2012-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 1009
- Registration Number
- NCT00862641
Effects of Body Mass Index on the Hyperemic Response to Regadenoson
- Conditions
- Decreased Vascular FlowEndothelial DysfunctionObesity
- Interventions
- First Posted Date
- 2009-03-11
- Last Posted Date
- 2011-05-24
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 30
- Registration Number
- NCT00859833
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
Multivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging
- First Posted Date
- 2009-03-09
- Last Posted Date
- 2016-05-11
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 120
- Registration Number
- NCT00857792
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Regadenoson R-T Perfusion Imaging Trial
- Conditions
- Coronary Artery DiseaseMyocardial Perfusion Abnormalities
- Interventions
- First Posted Date
- 2009-02-05
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 100
- Registration Number
- NCT00837369
- Locations
- 🇺🇸
University of Nebraska Medicial Center, Omaha, Nebraska, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)
- Conditions
- Coronary Artery Disease (CAD)
- Interventions
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 347
- Registration Number
- NCT00826280
Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)
- Conditions
- Coronary Artery DiseaseAsthmaChronic Obstructive Pulmonary Disease (COPD)Angina
- Interventions
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2018-09-26
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 14
- Registration Number
- NCT00763035
- Locations
- 🇺🇸
WAKE FOREST UNIVERSITY Baptist Medical Center, Winston-Salem, North Carolina, United States
ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1231
- Registration Number
- NCT00208299
- Locations
- 🇺🇸
Multiple study locations (see Central Contact); CV Therapeutics, Inc., Palo Alto, California, United States
ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 787
- Registration Number
- NCT00208312
- Locations
- 🇺🇸
Multiple study locations (see Central Contact); CV Therapeutics, Inc., Palo Alto, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.